The duration of oral anticoagulant therapy after a second episode of venous thromboembolism

Author(s): Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, et al.

Abstract

Background: A consensus has not been reached about the optimal duration of oral anticoagulant therapy after a second episode of venous thromboembolism.

Methods: In a multicenter trial, we compared six months of oral anticoagulant therapy with anticoagulant therapy continued indefinitely in patients who had had a second episode of venous thromboembolism. Of 227 patients enrolled, 111 were randomly assigned to six months of anticoagulation and 116 were assigned to receive anticoagulant therapy indefinitely; for both groups, the target international normalized ratio was 2.0 to 2.85. The initial episodes of deep-vein thrombosis (n = 193) and pulmonary embolism (n = 34), as well as recurrent episodes, were all objectively confirmed.

Results: After four years of follow-up, there were 26 recurrences of venous thromboembolism that fulfilled the diagnostic criteria, 23 in the group assigned to six months of therapy (20.7 percent) and 3 in the group assigned to continuing therapy (2.6 percent). The relative risk of recurrence in the group assigned to six months of therapy, as compared with the group assigned to therapy of indefinite duration, was 8.0 (95 percent confidence interval, 2.5 to 25.9). There were 13 major hemorrhages, 3 in the six-month group, (2.7 percent) and 10 in the infinite-treatment group (8.6 percent). The relative risk of major hemorrhage in the six-month group, as compared with the infinite-treatment group was 0.3 (95 percent confidence interval, 0.1 to 1.1). There was no difference in mortality between the two groups.

Conclusions: Prophylactic oral anticoagulation that was continued for an indefinite period after a second episode of venous thromboembolism was associated with a much lower rate of recurrence during four years of follow-up than treatment for six months. However, there was a trend toward a higher risk of major hemorrhage when anticoagulation was continued indefinitely.

Similar Articles

A prospective study of the incidence of deep-vein thrombosis within a defined urban population

Author(s): Nordström M, Lindblad B, Bergqvist D, Kjellström T

A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism

Author(s): Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, et al.

Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study

Author(s): Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, et al.

Age, an independent risk factor for thrombosis

Author(s): MahéI, Caulin C, Bergmann JF

Immobilization and the risk of venous thromboembolism

Author(s): Pottier P, Hardouin JB, Lejeune S, Jolliet P, Gillet B, et al.

Management of pulmonary embolism in a cardiology department

Author(s): OuldzeinH, Nourredine A, Cherradi R, Rahal N, Mechmeche R, et al.

Prolonged work- and computer-related seated immobility and risk of venous thromboembolism

Author(s): Healy B, Levin E, Perrin K, Weatherall M, Beasley R

Venous thromboembolism in Jamaican women: experience in a university hospital in Kingston

Author(s): Fletcher HM, Wharfe G, Williams NP, Pedican M, Brooks A, et al.

A prospective study of risk factors for pulmonary embolism in women

Author(s): Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, et al.

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Author(s): Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, et al.

Epidemiology of acute deep vein thrombosis

Author(s): BulgerCM, Jacobs C, Patel NH

Hormonal contraception and risk of venous thromboembolism: national follow-up study

Author(s): Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C

Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study

Author(s): Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, et al.

Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study

Author(s): Middeldorp S, Meijers JC, van den Ende AE, van Enk A, Bouma BN, et al.

Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives

Author(s): Alhenc-Gelas M, Plu-Bureau G, Guillonneau S, Kirzin JM, Aiach M, et al.

Effect of four different oral contraceptives on various sex hormones and serum-binding globulins

Author(s): Wiegratz I, Kutschera E, Lee JH, Moore C, Mellinger U, et al.

[Upper limb deep venous thrombosis]

Author(s): Benhamou Y, Marie I, David N, Gbaguidi X, Cailleux N, et al.

Old and new risk factors for upper extremity deep venous thrombosis

Author(s): Blom JW, Doggen CJ, Osanto S, Rosendaal FR

Homocysteine and vascular disease

Author(s): Hankey GJ, Eikelboom JW

The long-term clinical course of acute deep venous thrombosis

Author(s): Prandoni P, Lensing AW, CogoA, Cuppini S, Villalta S, et al.